JENNEREX AND LEE’S PHARMACEUTICALS ANNOUNCE PARTNERSHIP FOR JX-594 IN CHINA 2009.11.23

 
LEE’S WILL FUND AND MANAGE CHINA CLINICAL SITES FOR JENNEREX’S PIVOTAL PROGRAM AND WILL RETAIN EXCLUSIVE LICENSE RIGHTS IN REGION

San Francisco, California and Hong Kong, November 18, 2009--Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee’s Pharmaceutical Holdings (HK Stock code: 8221), the execution of a collaboration and license agreement for Jennerex’s lead product candidate, JX-594, in certain Asian territories. Lee’s is a fully integrated pharmaceutical group with operations in People’s Republic of China (PRC), Hong Kong and Macau.
 
  Download  


© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD